Get the Stockscreener App
59.56
0.83%
0.49
Pre-market:
58.81
-0.75
-1.26%
Vericel Corp stock is traded at $59.56, with a volume of 378.28K.
It is up +0.83% in the last 24 hours and up +5.42% over the past month.
See More
Previous Close:
$59.07
Open:
$59.44
24h Volume:
378.28K
Relative Volume:
0.97
Market Cap:
$2.92B
Revenue:
$226.84M
Net Income/Loss:
$3.55M
P/E Ratio:
850.86
EPS:
0.07
Net Cash Flow:
$-12.02M
1W Performance:
+1.52%
1M Performance:
+5.42%
6M Performance:
+18.86%
1Y Performance:
+50.14%
1-Day Range:
$58.49
$60.15
1-Week Range:
$53.00
$60.15
52-Week Range:
$39.12
$61.49
Vericel Corp Stock (VCEL) Company Profile
Name
Vericel Corp
Sector
Industry
Phone
(734) 930-5555
Address
64 SIDNEY ST., CAMBRIDGE, MA
Compare VCEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VCEL
Vericel Corp
|
59.56 | 2.92B | 226.84M | 3.55M | -12.02M | 0.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vericel Corp Stock (VCEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-09-24 | Initiated | Canaccord Genuity | Buy |
| Jun-20-24 | Initiated | TD Cowen | Buy |
| Jan-25-24 | Upgrade | Truist | Hold → Buy |
| Aug-08-23 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-10-22 | Downgrade | BTIG Research | Buy → Neutral |
| Nov-09-22 | Downgrade | Truist | Buy → Hold |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Jan-11-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-18-20 | Initiated | Stephens | Overweight |
| Sep-17-20 | Initiated | Truist | Buy |
| Oct-09-19 | Initiated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Needham | Buy → Hold |
| Aug-08-18 | Reiterated | Needham | Buy |
| Jul-16-18 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Apr-04-18 | Initiated | Leerink Partners | Outperform |
| Mar-06-18 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-06-18 | Reiterated | Needham | Buy |
| Mar-05-18 | Reiterated | BTIG Research | Buy |
| Jun-21-17 | Initiated | BTIG Research | Buy |
| Mar-13-17 | Reiterated | Needham | Buy |
| Dec-22-16 | Initiated | Piper Jaffray | Overweight |
| Nov-09-16 | Reiterated | Needham | Buy |
| Apr-05-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-11-16 | Upgrade | Needham | Hold → Buy |
View All
Vericel Corp Stock (VCEL) Latest News
Burns Pipeline 2024: In-depth Clinical Trials Analysis and Emerging Therapies Report by DelveInsight | MediWound, Kaken Pharma, Kerecis, Medline, Mallinckrodt Pharma, Avita Medical, Vericel Corp - The Globe and Mail
Equities Analysts Set Expectations for Vericel Q3 Earnings - MarketBeat
Vericel (NASDAQ:VCEL) Earns “Overweight” Rating from Stephens - Defense World
FY2024 EPS Estimates for Vericel Reduced by HC Wainwright - Defense World
FY2024 Earnings Estimate for Vericel Issued By HC Wainwright - MarketBeat
Analyst supports Vericel stock outlook citing MACI Arthro synergies and expansion plans - Investing.com
Vericel (NASDAQ:VCEL) Shares Gap DownShould You Sell? - MarketBeat
Vericel (NASDAQ:VCEL) Receives "Overweight" Rating from Stephens - MarketBeat
Applied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
HC Wainwright Reaffirms "Buy" Rating for Vericel (NASDAQ:VCEL) - MarketBeat
Beyond The Numbers: 5 Analysts Discuss Vericel Stock - Benzinga
Canaccord reaffirms Vericel stock buy rating on preliminary Q4 results - Investing.com
Vericel's preliminary Q4 revenue falls short of analyst expectations; shares fall 11% post market - Investing.com
Vericel expects 2024 net revenue in range of $237 to $237.5 million - MSN
Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets - Yahoo Finance
Vericel Co. (NASDAQ:VCEL) Receives $61.14 Consensus PT from Analysts - Defense World
JPMorgan Chase & Co. Has $19.08 Million Stake in Vericel Co. (NASDAQ:VCEL) - Defense World
Vericel to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 - Yahoo Finance
Brokerages Set Vericel Co. (NASDAQ:VCEL) Price Target at $61.14 - MarketBeat
Vericel (NASDAQ:VCEL) Shares Cross Above 200 Day Moving AverageShould You Sell? - MarketBeat
Vericel Corp prices $17 million public offering of common stock - Reuters
5 Best Stem Cell Companies to Invest In (January 2025) - Securities.io
Vericel Co. (NASDAQ:VCEL) Shares Sold by Principal Financial Group Inc. - Defense World
Principal Financial Group Inc. Has $10.64 Million Position in Vericel Co. (NASDAQ:VCEL) - MarketBeat
MML Investors Services LLC Raises Stock Position in Vericel Co. (NASDAQ:VCEL) - Defense World
Geode Capital Management LLC Grows Stock Position in Vericel Co. (NASDAQ:VCEL) - MarketBeat
Vericel Co. (NASDAQ:VCEL) Shares Acquired by Geode Capital Management LLC - Defense World
Vericel (NASDAQ:VCEL) Upgraded at StockNews.com - MarketBeat
Financial Review: Surrozen (NASDAQ:SRZN) & Vericel (NASDAQ:VCEL) - Defense World
Stifel Financial Corp Increases Holdings in Vericel Co. (NASDAQ:VCEL) - Defense World
Barclays PLC Boosts Stock Holdings in Vericel Co. (NASDAQ:VCEL) - MarketBeat
Vericel (NASDAQ:VCEL) Stock Price Expected to Rise, Truist Financial Analyst Says - Defense World
Vericel price target raised to $67 from $61 at Truist - Yahoo Finance
Vericel shares target upgraded, Buy rating on robust growth trajectory - Investing.com
Truist Financial Issues Positive Forecast for Vericel (NASDAQ:VCEL) Stock Price - MarketBeat
Vericel's SWOT analysis: MACI arthro approval boosts cartilage repair stock - Investing.com
Vericel (NASDAQ:VCEL) Shares Up 5.3%Here's What Happened - MarketBeat
TD Cowen lifts Vericel shares target, maintains buy rating on growth prospects - Investing.com
Brokerages Set Vericel Co. (NASDAQ:VCEL) Price Target at $59.71 - Defense World
State Street Corp Sells 55,227 Shares of Vericel Co. (NASDAQ:VCEL) - MarketBeat
Bioengineered Artificial Skin Market Growth in Future Scope - openPR
Financial Contrast: Vericel (NASDAQ:VCEL) versus HilleVax (NASDAQ:HLVX) - Defense World
Vericel Co. (NASDAQ:VCEL) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Vericel (NASDAQ:VCEL) Rating Lowered to “Sell” at StockNews.com - Defense World
Wellington Management Group LLP Grows Stock Position in Vericel Co. (NASDAQ:VCEL) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 12,375 Shares of Vericel Co. (NASDAQ:VCEL) - MarketBeat
Vericel's SWOT analysis: arthroscopic MACI approval boosts stock outlook - Investing.com
BNP Paribas Financial Markets Has $1.35 Million Position in Vericel Co. (NASDAQ:VCEL) - Defense World
Castleark Management LLC Sells 64,040 Shares of Vericel Co. (NASDAQ:VCEL) - MarketBeat
Insider Sell: Paul Wotton Sells 2,600 Shares of Vericel Corp (VC - GuruFocus.com
Vericel director Paul Wotton sells $152,672 in stock By Investing.com - Investing.com Canada
Vericel Corp Stock (VCEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):